Company profile: Jnana Therapeutics
1.1 - Company Overview
Company description
- Provider of chemoproteomics-driven drug discovery via its RAPID platform to identify small-molecule medicines for a range of diseases; developing JNT-517, an allosteric SLC6A19 inhibitor for phenylketonuria to reduce plasma phenylalanine; advancing programs for autoimmune and inflammatory conditions; and collaborating with biopharma in cancer, immune-mediated, and neurological diseases.
Products and services
- Collaborations in Cancer, Immune-Mediated, and Neurological Diseases: Biopharma-partnered initiatives extending RAPID platform application beyond internal focus to cancer, immune-mediated, and neurological indications for small-molecule discovery
- JNT-517: An allosteric inhibitor of SLC6A19 aimed at treating phenylketonuria (PKU) by reducing plasma phenylalanine levels
- RAPID Platform: A chemoproteomics-based discovery platform that produces small-molecule medicines targeting a range of diseases, enabling drug discovery across diverse indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Jnana Therapeutics
AbbVie
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies and precision medicine across immunology, oncology, neuroscience, virology, and aesthetics. Offers HUMIRA for autoimmune conditions, IMBRUVICA for certain cancers, and RINVOQ for inflammatory diseases. Delivers genomics research and the AbbVie R&D Convergence Hub (ARCH) to integrate data and advance personalized drug discovery and treatment insights.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AbbVie company profile →
Acceleron Pharma
HQ: United States
Website
- Description: Provider of novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases; engaged in developing, manufacturing, and commercializing these products, including the ACE-011 program, a novel bone-forming program.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acceleron Pharma company profile →
Arena Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical research and development focused on cardiovascular, central nervous system, inflammatory, and metabolic diseases, including the development of lorcaserin hydrochloride, which has reported positive clinical trial data. Headquartered in San Diego, CA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arena Pharmaceuticals company profile →
Artizan Biosciences
HQ: United States
Website
- Description: Provider of drug discovery and development focused on diseases involving the human intestinal microbiota.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artizan Biosciences company profile →
Novo Nordisk
HQ: Denmark
Website
- Description: Provider of insulin and other diabetes drugs for chronic diseases, GLP-1 treatments for type 2 diabetes, obesity care pharmaceuticals, Mim8 for haemophilia A (weekly or monthly dosing), and ReMed, a recycling program for used injection pens, with a focus on pioneering scientific breakthroughs and expanding access to medicines to prevent and cure disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Novo Nordisk company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Jnana Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Jnana Therapeutics
2.2 - Growth funds investing in similar companies to Jnana Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Jnana Therapeutics
4.2 - Public trading comparable groups for Jnana Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →